Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Neil S Kidambi, Omar H. Elsayed, Rif S. El‐Mallakh
Abstract
Abstract: Schizophrenia is a severe mental illness that has its onset in late adolescence or early adulthood and is associated with significant dysfunction across multiple domains. The pathogenesis of schizophrenia remains unknown, but physiologic understanding of the illness has been driven by the dopamine hypothesis. However, acetylcholine (ACh) clearly plays a role with mixed results regarding effect on psychosis. Selective muscarinic M 1 and M 4 agonists, such as xanomeline, originally developed to aid in cognitive loss with Alzheimer’s, showed promise in proof-of-concept study in 20 patients with schizophrenia. Unfortunately, tolerability problems made muscarinic agonists impractical in either condition. However, coadministration of trospium, a lipophobic, non-selective muscarinic antagonist previously used for the treatment of overactive bladder, with xanomeline resulted in a significant reduction of cholinergic adverse effects. A recent randomized, placebo-controlled study of the antipsychotic effects of this combination in 182 patients with acute psychosis revealed improved tolerability with 80% of subjects staying to the end of the 5 weeks study. At the end of the trial, the treatment group saw a − 17.4 change in the positive and negative symptom scale (PANSS) score from baseline compared to a − 5.9 change in the placebo arm ( P < 0.001). Furthermore, the negative symptom subscore, was also superior in the active arm ( P < 0.001). These early studies are exciting because they suggest that the cholinergic system may be recruited to treat a severe and disabling disorder with suboptimal treatment options. Xanomeline-trospium combination is currently in phase III studies. Keywords: muscarinic agents, M1 agonist, M4 agonist, non-selective anticholinergic